Guangzhou Development Zone Sees 21 Biopharmaceutical Companies Listed

InnoGen Pharma Rings the Bell on Hong Kong Stock Exchange

On August 15, Guangzhou Innogen Pharmaceutical Group Co., Ltd. (InnoGen Pharma) officially debuted on the Hong Kong Stock Exchange under the stock code 2591.HK, with an issue price of HKD 18.68 per share.

Founded in 2014, InnoGen Pharma is a biotechnology company focusing on innovative therapies for diabetes and other metabolic diseases. In March 2025, the company established its headquarters on Guangzhou International Biotech Island, further strengthening the biopharmaceutical industry ecosystem in Guangzhou Development Zone and Huangpu District. This successful listing adds another member to Huangpu District's growing roster of publicly traded companies.

To date, Guangzhou Development Zone is home to 89 listed companies—ranking first among all national economic development zones in China—with 21 of these being biopharmaceutical companies.

According to official data, since opening in July 2011, Guangzhou International Biotech Island has attracted nearly 700 biopharmaceutical companies, making it China's only biotech park to simultaneously house national laboratories, major national scientific facilities, and international large-scale scientific programs. Meanwhile, Guangzhou Development Zone and Huangpu District are accelerating the formation of a coordinated biopharmaceutical development strategy featuring "R&D on Biotech Island, pilot testing in Science City, and manufacturing in Knowledge City."